1
|
Vignisse J, Steinbusch HWM, Grigoriev V, Bolkunov A, Proshin A, Bettendorff L, Bachurin S, Strekalova T. Concomitant manipulation of murine NMDA- and AMPA-receptors to produce pro-cognitive drug effects in mice. Eur Neuropsychopharmacol 2014; 24:309-20. [PMID: 23993168 DOI: 10.1016/j.euroneuro.2013.06.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2012] [Revised: 06/18/2013] [Accepted: 06/23/2013] [Indexed: 02/07/2023]
Abstract
Bifunctional drug therapy targeting distinct receptor signalling systems can generate increased efficacy at lower concentrations compared to monofunctional therapy. Non-competitive blockade of the NMDA receptors or the potentiation of AMPA receptors is well documented to result in memory enhancement. Here, we compared the efficacy of the low-affinity NMDA receptor blocker memantine or the positive modulator of AMPA receptor QXX (in C57BL/6J at 1 or 5mg/kg, ip) with new derivatives of isothiourea (0.5-1 mg/kg, ip) that have bifunctional efficacy. Low-affinity NMDA blockade by these derivatives was achieved by introducing greater flexibility into the molecule, and AMPA receptor stimulation was produced by a sulfamide-containing derivative of isothiourea. Contextual learning was examined in a step-down avoidance task and extinction of contextual memory was studied in a fear-conditioning paradigm. Memantine enhanced contextual learning while QXX facilitated memory extinction; both drugs were effective at 5 mg/kg. The new derivative IPAC-5 elevated memory scores in both tasks at the dose 0.5 mg/kg and exhibited the lowest IC₅₀ values of NMDA receptor blockade and highest potency of AMPA receptor stimulation. Thus, among the new drugs tested, IPAC-5 replicated the properties of memantine and QXX in one administration with increased potency. Our data suggest that a concomitant manipulation of NMDA- and AMPA-receptors results in pro-cognitive effects and supports the concept bifunctional drug therapy as a promising strategy to replace monofunctional therapies with greater efficacy and improved compliance.
Collapse
Affiliation(s)
- Julie Vignisse
- School for Mental Health and Neuroscience, Department of Neuroscience, Maastricht University, Universiteitssingel 40, NL 6229ER Maastricht, Netherlands; GIGA Neuroscience, University of Liege, Avenu de l'Hopital 1, B36 4000 Liege, Belgium
| | - Harry W M Steinbusch
- School for Mental Health and Neuroscience, Department of Neuroscience, Maastricht University, Universiteitssingel 40, NL 6229ER Maastricht, Netherlands
| | - Vladimir Grigoriev
- Institute of Physiologically Active Compounds, Laboratory of Neurochemistry, Russian Academy of Sciences, Chernogolovka, Severnii proesd 1, 142432 Moscow Region, Russia
| | - Alexei Bolkunov
- Institute of Physiologically Active Compounds, Laboratory of Neurochemistry, Russian Academy of Sciences, Chernogolovka, Severnii proesd 1, 142432 Moscow Region, Russia
| | - Alexey Proshin
- Institute of Physiologically Active Compounds, Laboratory of Neurochemistry, Russian Academy of Sciences, Chernogolovka, Severnii proesd 1, 142432 Moscow Region, Russia
| | - Lucien Bettendorff
- GIGA Neuroscience, University of Liege, Avenu de l'Hopital 1, B36 4000 Liege, Belgium
| | - Sergey Bachurin
- Institute of Physiologically Active Compounds, Laboratory of Neurochemistry, Russian Academy of Sciences, Chernogolovka, Severnii proesd 1, 142432 Moscow Region, Russia.
| | - Tatyana Strekalova
- School for Mental Health and Neuroscience, Department of Neuroscience, Maastricht University, Universiteitssingel 40, NL 6229ER Maastricht, Netherlands
| |
Collapse
|
2
|
Jamadar S, DeVito EE, Jiantonio RE, Meda SA, Stevens MC, Potenza MN, Krystal JH, Pearlson GD. Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism. Psychopharmacology (Berl) 2012; 222:129-40. [PMID: 22311382 PMCID: PMC3674025 DOI: 10.1007/s00213-011-2628-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2011] [Accepted: 12/19/2011] [Indexed: 11/25/2022]
Abstract
RATIONALE Individuals with a family history of alcoholism (family history positive [FHP]) show higher alcoholism rates and are more impulsive than those without such a family history (family history negative [FHN]), possibly due to altered N-methyl-D-aspartate (NMDA) receptor function. OBJECTIVES We investigated whether memantine, an NMDA receptor antagonist, differentially influences impulsivity measures and Go/No-Go behavior and fMRI activity in matched FHP and FHN individuals. METHODS On separate days, participants received a single dose of 40 mg memantine or identical-appearing placebo. RESULTS No group performance differences were observed on placebo for Go correct hit or No-Go false alarm reaction time on the Go/No-Go task. During fMRI, right cingulate activation differed for FHP vs. FHN subjects during No-Go correct rejects. Memantine had attenuated effects in FHP vs. FHN subjects: For No-Go false alarms, memantine was associated with limited reduction in subcortical, cingulate, and temporal regions in FHP subjects and reduced activity in fronto-striatal-parietal networks in FHN subjects. For No-Go correct rejects, memantine (relative to placebo) reduced activity in left cingulate and caudate in FHP but not FHN subjects. CONCLUSIONS Lower sensitivity to the effects of memantine in FHP subjects is consistent with greater NMDA receptor function in this group.
Collapse
Affiliation(s)
- S. Jamadar
- Olin Neuropsychiatry Research Center, Institute of Living, Hartford, CT 06106, USA
| | - E. E. DeVito
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - R. E. Jiantonio
- Olin Neuropsychiatry Research Center, Institute of Living, Hartford, CT 06106, USA
| | - S. A. Meda
- Olin Neuropsychiatry Research Center, Institute of Living, Hartford, CT 06106, USA,Center of Human Genetics and Research, Vanderbilt University, Nashville, TN, USA
| | - M. C. Stevens
- Olin Neuropsychiatry Research Center, Institute of Living, Hartford, CT 06106, USA,Department of Psychiatry, Yale University, New Haven, CT, USA
| | - M. N. Potenza
- Department of Psychiatry, Yale University, New Haven, CT, USA,Department of Neurobiology, Yale University, New Haven, CT, USA,Child Study Center, Yale University, New Haven, CT, USA
| | - J. H. Krystal
- Department of Psychiatry, Yale University, New Haven, CT, USA,Clinical Neuroscience Division, VA National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT, USA,Psychiatry Services, Yale-New Haven Hospital, New Haven, CT, USA
| | - G. D. Pearlson
- Olin Neuropsychiatry Research Center, Institute of Living, Hartford, CT 06106, USA,Department of Psychiatry, Yale University, New Haven, CT, USA,Department of Neurobiology, Yale University, New Haven, CT, USA
| |
Collapse
|